PriceTargets.com logo

Oncternal Therapeutics - ONCT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 466.04 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.06 As of 10/5/2022 02:21 PM ET
▼ -0.05 (-4.50%)

This chart shows the closing price for ONCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oncternal Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONCT

Analyst Price Target is $6.00
▲ +466.04% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Oncternal Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 466.04% upside from the last price of $1.06.

This chart shows the closing price for ONCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Oncternal Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/13/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2022HC WainwrightLower TargetBuy$8.00 ➝ $7.00Low
5/10/2022Maxim GroupInitiated CoverageBuyMedium
2/24/2022BTIG ResearchInitiated CoverageBuy$5.00High
9/21/2021HC WainwrightReiterated RatingBuy$9.00High
4/16/2021HC WainwrightReiterated RatingBuy$9.00Medium
4/6/2021OppenheimerInitiated CoverageOutperform$14.00High
3/30/2021Brookline Capital ManagementReiterated RatingBuy$16.00High
3/30/2021Brookline Capital AcquisitionInitiated CoverageBuy$16.00High
3/12/2021HC WainwrightBoost TargetBuy$8.00 ➝ $9.00High
2/23/2021Northland SecuritiesInitiated CoverageOutperform$21.00High
11/12/2020HC WainwrightReiterated RatingBuyLow
9/21/2020HC WainwrightReiterated RatingBuy$8.00Low
8/10/2020HC WainwrightInitiated CoverageBuy$8.00Medium
(Data available from 10/5/2017 forward)

News Sentiment Rating

1.26 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/9/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/8/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2022

Current Sentiment

  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Oncternal Therapeutics logo
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.06
Low: $1.02
High: $1.08

50 Day Range

MA: $1.06
Low: $0.79
High: $1.33

52 Week Range

Now: $1.06
Low: $0.69
High: $4.49

Volume

6,827 shs

Average Volume

303,158 shs

Market Capitalization

$56.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncternal Therapeutics?

The following equities research analysts have issued stock ratings on Oncternal Therapeutics in the last year: BTIG Research, HC Wainwright, Maxim Group, and StockNews.com.
View the latest analyst ratings for ONCT.

What is the current price target for Oncternal Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Oncternal Therapeutics in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 440.5%. HC Wainwright has the highest price target set, predicting ONCT will reach $7.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $5.00 for Oncternal Therapeutics in the next year.
View the latest price targets for ONCT.

What is the current consensus analyst rating for Oncternal Therapeutics?

Oncternal Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ONCT will outperform the market and that investors should add to their positions of Oncternal Therapeutics.
View the latest ratings for ONCT.

What other companies compete with Oncternal Therapeutics?

Other companies that are similar to Oncternal Therapeutics include Applied Therapeutics, Aptorum Group, LumiraDx, Longboard Pharmaceuticals and LifeVantage. Learn More about companies similar to Oncternal Therapeutics.

How do I contact Oncternal Therapeutics' investor relations team?

Oncternal Therapeutics' physical mailing address is 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company's listed phone number is (858) 434-1113 and its investor relations email address is [email protected] The official website for Oncternal Therapeutics is www.oncternal.com. Learn More about contacing Oncternal Therapeutics investor relations.